SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline

CAR-T Digest - August 2020

16 July 2024: SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline

SOTIO has agreed to pay Biocytogen up to $325.5 million in upfront and milestone fees for rights to targeting molecules, combining bispecifics with its ADC capabilities
Biocytogen uses transgenic mice to generate bispecific antibodies that can be conjugated to cytotoxic payloads, creating ADCs with enhanced cancer-killing power and reduced off-target toxicity
Over the past eight years, Sotio has enhanced its ADC capabilities through deals with NBE-Therapeutics, LegoChem Biosciences, and Synaffix, gaining access to conjugation technology, payloads, and ADC candidates
The collaboration with Biocytogen gives Sotio the option to license multiple fully human bispecific antibodies
SOTIO has selected initial targets for its bispecific program, focusing its pipeline heavily on ADCs